TransThera seeks Hong Kong IPO to sustain cancer drug research
The developer of drugs for advanced or recurrent cancers has already conducted nine financing rounds, but will not start generating commercial revenue before 2026, as all its products are still…
Recent Articles
RELATED ARTICLES
-
Cancer drug maker Genfleet joins Hong Kong IPO influx
-
A blockbuster cancer drug? TYK’s claims go under the microscope
2410.HK
-
Everest Medicines eyes mRNA tumor vaccines as drug valuations rebound
1952.HK
-
Cancer drug maker Biostar shines on Hong Kong market debut
2563.HK
- Cash-strapped Mirxes looks for lifeline in blood-based cancer detection
-
Xuanzhu Biopharm set for spin-off in Hong Kong IPO
0460.HK
-
Everest Medicines drives growth with AI-powered mRNA pipeline
1952.HK
